The information contained in this area of the website is for the purposes of AIM Rule 26.
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end‐to‐end services provider enabled by DXRX ‐ our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2,500 laboratories in 51 countries. www.diaceutics.com
About DXRX ‐ The Diagnostic Network®
DXRX is Diaceutics' proprietary diagnostic network solution for precision medicine. DXRX is an end‐to‐end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.
A full description of the business can be found here - Company Profile
Board of Directors
The names of the directors and biographical details can be found here - Board of Directors
Information on Corporate Governance can be found here - Corporate Governance
UK Takeover Code Applicability
The Company is subject to the provisions of the UK City Code on Takeover and Mergers.
Country of Incorporation & Operations
The Company was incorporated and registered in Northern Ireland with registered number NI055207. Its main country of operation is Northern Ireland with wholly owned subsidiary undertakings in Northern Ireland, the Republic of Ireland, the US and Singapore.
Registered Office and principal trading address
55-59 Adelaide Street
Current Constitutional Documents
Details of Restrictions on the transfer of Securities
There are no restrictions on the transfer of the Company’s ordinary shares.
Statement of the Rights of Shareholders
The rights of shareholders are governed by UK law.
Details of any other exchanges or trading platform
The securities of the Company are traded on the AIM market operated by the London Stock Exchange plc. Its shares have not been admitted, nor have any applications been made, for any of its shares to be admitted or traded on any other exchanges or trading platform.
AIM securities in issue: 84,068,923
The percentage of AIM securities not in public hands at 9th April 2021 was 37.86%.
The identity and shareholdings of the Company's significant shareholders can be found here - Significant Shareholders
Documents sent to Shareholders
The documents sent to shareholders can be found here.
|Circular and Notice of General Meeting June 2020||Notice of Annual General Meeting 2021|
|Form of Proxy for General Meeting June 2020||Form of Proxy for Annual General Meeting 2021|
To view the details of the Company’s Advisers please click here
To access notifications made by the Company please click here.
This information was last updated on 9th April 2021.